Ypsomed Holding AG - Company Profile
Powered by 
All the sales intelligence you need on Ypsomed Holding AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Ypsomed Holding AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Ypsomed Holding AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Ypsomed Holding AG (Ypsomed) is a medical device company. It designs, develops, and manufactures injection and infusion systems for self-medication and offers related services. The company's products find application in the treatment of diabetes, infertility, growth disorders and various other clinical indications. Ypsomed's product portfolio includes autoinjectors, dual chamber pens, and pen injectors. The company also provides services ranging from design and development projects, flexible prototyping, human factors engineering, monitoring services, therapy management and IP landscape management to manufacturing and assembly infrastructure and registration support. Ypsomed offers solutions to physicians, and pharmaceutical and biotechnology companies. The company has operations in Switzerland, Europe, and North America, among others. Ypsomed is headquartered in Burgdorf, Switzerland.
Headquarters
Switzerland
Address
Brunnmattstrasse 6, Burgdorf, 3400
Website
www.ypsomed.com
Telephone
41 34 4244111
No of Employees
2,753
Industry
Medical Equipment
Ticker Symbol & Exchange
YPSN (SWF)
Revenue (2024)
$850.5M
36.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
11.7%
(2024 vs 2023)
Market Cap*
$6.2B
Net Profit Margin (2024)
XYZ
-18.2%
(2024 vs 2023)
* As of and is in US$
Ypsomed Holding AG premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Delivery Systems: | Contract Manufacturing | Penfine |
| Autoinjectors | Design and Development Services | Universal Click |
| Pen Injectors | Prototyping | Humatro-Pen |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
| XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Corporate Changes/Expansions | In April, the company opened its new tool manufacturing facility in Solothurn, Switzerland. |
| 2026 | Contracts/Agreements | In January, the company and BD expanded their collaboration by developing a 5.5 mL version of the BD Neopak XtraFlow syringe. |
| 2025 | Divestiture | In November, the company announced the sale of its subsidiary Ypsotec to Callista Asset Management 32 GmbH (Callista). |
Competitor Comparison
| Key Parameters | Ypsomed Holding AG | Johnson & Johnson | Eli Lilly and Co | Sanofi | Novo Nordisk AS |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | France | Denmark |
| City | Burgdorf | New Brunswick | Indianapolis | Paris | Bagsvaerd |
| State/Province | - | New Jersey | Indiana | Ile-de-France | - |
| No. of Employees | 2,753 | 138,200 | 50,605 | 76,493 | 64,974 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gilbert Achermann | Chairman | Executive Board | 2022 | 62 |
| Simon Michel | Chief Executive Officer; Director | Executive Board | 2022 | 49 |
| Samuel Kunzli | Chief Financial Officer | Senior Management | 2024 | 42 |
| Frank Mengis | Chief Operating Officer | Senior Management | 2015 | 62 |
| Nicolas Meyer | Chief Legal Officer | Senior Management | 2023 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer